Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for Aspirin Desensitization in AERD
NCT00555971Phase 4Completed
- Start
- May 2006
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Aspirin Exacerbated Respiratory Disease (AERD) comparing Omalizumab Group with Placebo Group (2 arms). Primary endpoint: Number of Participants Without Respiratory Reaction During Aspirin Desensitization. Started May 2006; status: completed.
02
Drugs
omalizumab
03
Conditions
Aspirin Exacerbated Respiratory Disease (AERD)
Beyond the preview
Go deeper on NCT00555971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00555971.